Mitsubishi Public Affairs Committee

Mitsubishi Space Software (MSS) began cancer clinical sequencing in April 2016, working in collaboration with the Hokkaido University Hospital’s Division of Clinical Cancer Genomics. Until then, the company’s role in this field had been in offering doctors a choice of therapeutic agents after analyzing data on diseases caused by gene mutations, on where mutations take place, and on the type of mutation. Cancer genome diagnostics is believed to be effective in treating inoperable cancers, advanced lung cancer, breast cancer, and colorectal cancer. The diagram below shows the diagnostic process flowline in which the company is responsible for Section 3, data quality checks and data correction.
     MSS entered the field of genomic data analysis over twenty years ago. Since then it has built up a high-precision data biobank and has recently completed development of algorithms and software capable of analyzing molecular targeted agent combinations approved for use in Japan. Currently, the number of medical institutions in Japan engaged in this type of advanced medical treatment has increased to over 20.

  The cancer genome diagnostic process: MSS is responsible for the tasks in section 3 . Letters A, C, G, and T are abbreviations for the four nucleotide bases of a DNA strand: adenine, cytosine, guanine, thymine.